{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:12:04Z","timestamp":1771621924728,"version":"3.50.1"},"reference-count":0,"publisher":"Romanian Society of Gastroenterology and Hepatology","issue":"4","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JGLD"],"abstract":"<jats:p>Background and Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir\/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir\/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir\/pibrentasvir.\r\nMethods: This observational, retrospective medical chart review study was based on a Patient Support Program for HCV-infected patients (HCV-PSP) attending clinical practices in Romania and initiating glecaprevir\/pibrentasvir between 01 February 2022 and 11 July 2023. Patients \u226518 years of age with compensated liver disease F0-F4 fibrosis grade treatment-na\u00efve or F0-F3 fibrosis grade treatment-experienced on previous interferon-based regimens from the HCV-PSP were included in the ODYSSEY study. Patients received glecaprevir\/pibrentasvir for at least 8 weeks. Sustained virological response (SVR) was assessed at 12 weeks after the 8-week treatment (SVR12). Analyses were conducted on the core population (CP) and the CP with sufficient follow-up data (CPSFU).\r\nResults: The CP and CPSFU included 2,240 and 2,165 patients, respectively. In both populations, most patients were female (\u226567.57%), aged &gt;50 years (\u226573.62%), and treatment-na\u00efve (\u226596.47%). F4 fibrosis was reported in 19% of patients. Hypertension was the most common relevant comorbidity, reported for 21% of patients; comorbidity rates increased with age. Overall SVR12 rates were 96.1% [95% confidence interval (CI): 95.2-96.8%) and 99.3% (95%CI: 98.9\u201399.6) in the CP and CPSFU, respectively. When stratified by gender, age category, comorbidities or fibrosis grade, SVR12 rates were &gt;92% in the CP [except for the subgroups of patients with chronic kidney disease (87.5%) and depressive-\/anxiety disorders (86.2%)] and \u226597.0% in the CPSFU. SVR12 rates were higher in female patients. In an exploratory analysis, in the CPSFU, the presence of diabetes mellitus [odds ratio (OR)=3.840; 95%CI: 1.093\u201313.495] and cardiovascular diseases (OR=7.904; 95%CI: 1.719-36.346) were associated with an increased probability to detect HCV RNA at 12 weeks post-treatment.\r\nConclusions: The 8-week treatment with glecaprevir\/pibrentasvir resulted in high SVR12 rates for multiple HCV-infected patient profiles encountered in real-life settings in Romania.<\/jats:p>","DOI":"10.15403\/jgld-5745","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T13:32:18Z","timestamp":1735392738000},"page":"503-509","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of 8-week Treatment with Glecaprevir\/Pibrentasvir in Treatment-na\u00efve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY)"],"prefix":"10.15403","volume":"33","author":[{"given":"Anca","family":"Trifan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Streinu-Cercel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustina","family":"Culinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Baroiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Dumitru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Pojoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Brisc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela Mihaela","family":"Brisc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Ionut","family":"Gheonea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Nicolae","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina Silvia","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Sorina","family":"Diaconu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mircea","family":"Diculescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6121","published-online":{"date-parts":[[2024,12,28]]},"container-title":["Journal of Gastrointestinal and Liver Diseases"],"original-title":[],"link":[{"URL":"https:\/\/www.jgld.ro\/jgld\/index.php\/jgld\/article\/download\/5745\/2138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jgld.ro\/jgld\/index.php\/jgld\/article\/download\/5745\/2137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:35:42Z","timestamp":1748633742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jgld.ro\/jgld\/index.php\/jgld\/article\/view\/5745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,28]]}},"URL":"https:\/\/doi.org\/10.15403\/jgld-5745","relation":{},"ISSN":["1842-1121","1841-8724"],"issn-type":[{"value":"1842-1121","type":"electronic"},{"value":"1841-8724","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,28]]}}}